Summary of opinion: Elucirem, 11/12/2025 Positive
Submitted by Anonymous (not verified) on 12 December 2025 - 13:00
Summary of opinion: Elucirem, 11/12/2025 Positive
Summary of opinion: Vueway, 11/12/2025 Positive
Submitted by Anonymous (not verified) on 12 December 2025 - 13:00
Summary of opinion: Vueway, 11/12/2025 Positive
Summary of opinion: Eylea, 11/12/2025 Positive
Submitted by Anonymous (not verified) on 12 December 2025 - 13:00
Summary of opinion: Eylea, 11/12/2025 Positive
Summary of opinion: Nucala, 11/12/2025 Positive
Submitted by Anonymous (not verified) on 12 December 2025 - 13:00
Summary of opinion: Nucala, 11/12/2025 Positive
Summary of opinion: Mounjaro, 11/12/2025 Positive
Submitted by Anonymous (not verified) on 12 December 2025 - 13:00
Summary of opinion: Mounjaro, 11/12/2025 Positive
Summary of opinion: Uplizna, 11/12/2025 Positive
Submitted by Anonymous (not verified) on 12 December 2025 - 13:00
Summary of opinion: Uplizna, 11/12/2025 Positive
Summary of opinion: Arexvy, 11/12/2025 Positive
Submitted by Anonymous (not verified) on 12 December 2025 - 13:00
Summary of opinion: Arexvy, 11/12/2025 Positive
Summary of opinion: Aspaveli, 11/12/2025 Positive
Submitted by Anonymous (not verified) on 12 December 2025 - 13:00
Summary of opinion: Aspaveli, 11/12/2025 Positive
Human medicines European public assessment report (EPAR): Prevymis, letermovir, Date of authorisation: 08/01/2018, Revision: 18, Status: Authorised
Submitted by Anonymous (not verified) on 12 December 2025 - 12:30
Human medicines European public assessment report (EPAR): Prevymis, letermovir, Date of authorisation: 08/01/2018, Revision: 18, Status: Authorised
Fourth European Medicines Agency - Medtech Europe bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, 21 November 2025
Submitted by Anonymous (not verified) on 12 December 2025 - 12:27
Fourth European Medicines Agency - Medtech Europe bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, 21 November 2025